Page 139 - 《中国药科大学学报》2026年第2期

第 57 卷第 2 期 张 靖，等：齐多夫定通过促进脂肪酸氧化改善高脂饮食诱导的大鼠代谢紊乱 265

pression through mitochondrial oxidative stress[J]. Physiol Ge- [24] Vial G, Lamarche F, Cottet-Rousselle C, et al. The mechanism
nomics, 2015, 47(10): 447-454. by which imeglimin inhibits gluconeogenesis in rat liver
[16] Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral cells[J]. Endocrinol Diabetes Metab, 2021, 4(2): e00211.
drugs[J]. Nat Med, 1995, 1(5): 417-422. [25] Nakamura MT, Yudell BE, Loor JJ. Regulation of energy
[17] Langtry HD, Campoli-Richards DM. Zidovudine: a review of metabolism by long-chain fatty acids[J]. Prog Lipid Res, 2014,
its pharmacodynamic and pharmacokinetic properties, and ther- 53: 124-144.
apeutic efficacy[J]. Drugs, 1989, 37(4): 408-450. [26] Dong J, Li MZ, Peng RS, et al. ACACA reduces lipid accumula-
[18] Foletto VS, da Rosa TF, Serafin MB, et al. Repositioning of tion through dual regulation of lipid metabolism and mitochon-
non-antibiotic drugs as an alternative to microbial resistance: a drial function via AMPK- PPARα- CPT1A axis[J]. J Transl
systematic review[J]. Int J Antimicrob Agents, 2021, 58(3): Med, 2024, 22(1): 196.
106380. [27] Chen H, Tan HB, Wan J, et al. PPAR-γ signaling in nonalco-
[19] Arruda EL, Japiassu KB, de Melo Souza PL, et al. Zidovudine holic fatty liver disease: pathogenesis and therapeutic targets[J].
glycosylation by filamentous fungi leads to a better redox stabi- Pharmacol Ther, 2023, 245: 108391.
lity and improved cytotoxicity in B16F10 murine melanoma [28] Sahu U, Villa E, Reczek CR, et al. Pyrimidines maintain mito-
cells[J]. Anticancer Agents Med Chem, 2020, 20(14): 1688- chondrial pyruvate oxidation to support de novo lipogenesis[J].
1694. Science, 2024, 383(6690): 1484-1492.
[20] Goodpaster BH, Sparks LM. Metabolic flexibility in health and [29] Amos A, Amos A, Wu LR, et al. The Warburg effect modu-
disease[J]. Cell Metab, 2017, 25(5): 1027-1036. lates DHODH role in ferroptosis: a review[J]. Cell Commun
[21] Yu MY, Alimujiang M, Hu LL, et al. Berberine alleviates lipid Signal, 2023, 21(1): 100.
metabolism disorders via inhibition of mitochondrial complex I [30] Fang JX, Uchiumi T, Yagi M, et al. Dihydro-orotate dehydroge-
in gut and liver[J]. Int J Biol Sci, 2021, 17(7): 1693-1707. nase is physically associated with the respiratory complex and
[22] Muller C, Lacroix-Malgras V, Kluza J, et al. The troglitazone its loss leads to mitochondrial dysfunction[J]. Biosci Rep, 2013,
derivative EP13 disrupts energy metabolism through respirato- 33(2): e00021.
ry chain complex I inhibition in breast cancer cells and potenti- [31] Lesner NP, Wang X, Chen ZK, et al. Differential requirements
ates the antiproliferative effect of glycolysis inhibitors[J]. Can- for mitochondrial electron transport chain components in the
cer Cell Int, 2024, 24(1): 132. adult murine liver[J]. eLife, 2022, 11: e80919.
[23] Su Y, Hou CJ, Wang ML, et al. Metformin induces mitochon- [32] Herrero Martín JC, Salegi Ansa B, Álvarez-Rivera G, et al. An
drial fission and reduces energy metabolism by targeting respi- ETFDH-driven metabolon supports OXPHOS efficiency in
ratory chain complex I in hepatic stellate cells to reverse liver fi- skeletal muscle by regulating coenzyme Q homeostasis[J]. Nat
brosis[J]. Int J Biochem Cell Biol, 2023, 157: 106375. Metab, 2024, 6(2): 209-225.